This course has expired. View available courses.
Endocrinology
Current Issues in the Management of Type 2 Diabetes – MOC Section 1
The 2018 Diabetes Canada Clinical Practice Guidelines provide clinicians with recommendations for the selection of therapy for type 2 diabetes. The guidelines provide a recommendation to customize antihyperglycemic agents (AHAs) based on patient and AHA properties.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
1
ACCREDITATION
MOC - Section 1
EXPIRY DATE
2019-11-16
The 2018 Diabetes Canada Clinical Practice Guidelines provide clinicians with recommendations for the selection of therapy for type 2 diabetes. The guidelines provide a recommendation to customize antihyperglycemic agents (AHAs) based on patient and AHA properties.
Faculty
Ronald Goldenberg, MD, FRCPC, FACE
Harpreet Bajaj, MD, MPH, FACE
Bertha Wong, MD, FRCPC
Learning objectives
Upon successful completion of this continuing education activity, the clinician will be better able to:
- Review the current evidence supporting the role of antihyperglycemic agents (AHA) for reducing cardiovascular and renal outcomes
- Summarize the importance of weight in the management of type 2 diabetes and the selection of antihyperglycemic agents
- Explain the pros and cons of basal insulin, GLP-1 receptor agonist (GLP-1 RA), and fixed dose insulin/GLP-1 RA as the first injectable therapy
- Develop a treatment strategy for the patient who is not reaching glycemic targets with basal insulin therapy +/- noninsulin AHAs